J&J receives subpoenas

Share this article:
US attorneys in Boston, Philadelphia and San Francisco have issued subpoenas to Johnson & Johnson for marketing materials involving three of its subsidiaries—Ortho-McNeil for Topamax, Janssen for Risperdal  and Scios for Natrecor.

J&J said the subpoenas seek information on its corporate supervision and oversight of the subsidiaries. A J&J statement said the company will cooperate.

Janssen, which increased Risperdal sales by 18% to $4.18 billion last year, received a subpoena in 2005 seeking information about the drug’s marketing and adverse reactions. Less than two years earlier, it received a subpoena from the Office of Personnel Management’s inspector-general seeking similar documents.

J&J’s Ortho-McNeil subsidiary, which increased Topamax sales by 21% to $2.03 billion last year, received a subpoena from the US Attorney’s Office in 2003 seeking documents relating to the drug’s marketing, including alleged “off-label” marketing, and a second subpoena last June.

In 2005, Scios received a subpoena from the US Attorney’s Office seeking documents regarding the sales and marketing of Natrecor, and Scios is responding to the subpoena, J&J said in the SEC filing.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.